Regenicin (OTCMKTS:RGIN – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.
Valuation & Earnings
This table compares Regenicin and NovoCure’s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Regenicin | N/A | N/A | -$640,000.00 | N/A | N/A |
NovoCure | $549.96 million | 3.30 | -$207.04 million | ($1.81) | -9.33 |
Regenicin has higher earnings, but lower revenue than NovoCure.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Regenicin | N/A | N/A | N/A |
NovoCure | -30.67% | -45.68% | -14.59% |
Institutional and Insider Ownership
0.0% of Regenicin shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 6.3% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Regenicin and NovoCure, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Regenicin | 0 | 0 | 0 | 0 | N/A |
NovoCure | 0 | 3 | 3 | 0 | 2.50 |
NovoCure has a consensus price target of $25.50, indicating a potential upside of 51.07%.
About Regenicin
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Receive News & Ratings for Regenicin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenicin and related companies with MarketBeat.com's FREE daily email newsletter.